# Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor

> **NCT02544451** · PHASE3 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 246 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** LUM/IVA
- **DRUG:** LUM/IVA

## Key facts

- **NCT ID:** NCT02544451
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2018-08
- **Final completion:** 2020-04
- **Target enrollment:** 246 (ACTUAL)
- **Last updated:** 2021-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02544451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02544451, "Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02544451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*